2025年1月7日 · The failure of AbbVie and Calico’s therapy to also hit the same goals in its own study arm points to “a difficulty with the drug class in a challenging disease.” In its own statement, Calico pointed to an assessment of muscle strength that hinted at slower deterioration among those given the company’s drug. Bill Cho, the company’s ...

2025年1月2日 · Developers of medicines known as “incretins” have been putting their therapies to such a test. Already, Novo showed its weight loss drug Wegovy can prevent an array of heart issues, evidence it has used to unlock broader insurance coverage. Next in line is Eli Lilly, which could have results from a cardiovascular outcomes trial of its own ...

2024年11月4日 · In addition, Ascendis could receive up to $77.5 million for each additional drug developed. Ascendis has won Food and Drug Administration approval of two products using its extended release technology, both in rare conditions. In partnering with Novo, Ascendis would gain entry into conditions that have blockbuster sales potential.

2024年12月13日 · That drug is in preclinical testing, as are two other candidates Nimble has disclosed for generalized myasthenia gravis and IBD. In addition to Nimble’s pipeline, AbbVie also noted that the acquisition will give it access to the Madison, Wisconsin-based company’s technology for synthesizing, screening and optimizing peptide-based drug ...

2023年11月6日 · Orum describes its therapy, dubbed ORM-6151, as an antibody-enabled protein degrader, merging the concept of an antibody-drug conjugate with the field of protein degradation. Orum said it has received Food and Drug Administration clearance to enter Phase 1 testing in acute myeloid leukemia and myelodysplastic syndromes.

2025年1月16日 · The pharma will pay $200 million to buy Nimble and a preclinical oral drug that blocks a protein known as IL-23 — the target of AbbVie’s injection Skyrizi. By Ned Pagliarulo • Dec. 13, 2024

2025年1月22日 · The placebo-controlled study will test the efficacy of Intellia’s drug, dubbed NTLA-2002, in 60 adults with either Type 1 or Type 2 HAE, which can cause severe swelling attacks. The company expects to complete enrollment in the second half of this year and, pending positive results, to submit for U.S. approval in 2026.

2024年12月9日 · The drug can cause side effects similar to that of menopause and was a “horrific” experience for Schott, who was about 13 years old when it was prescribed to her. Within the past decade, two other products have been approved by the FDA for pain management with endometriosis: AbbVie’s Orilissa in 2018 , and Pfizer and partner Myovant ...

2025年1月13日 · Scorpion has been collaborating with Pfizer to study STX-678 together with a so-called CDK4 inhibitor. Lilly sells a drug, called Verzenio, that similarly targets CDK4 alongside a related protein. The deal will expand a cancer drug division Lilly has poured considerable resources into as a complement to its lucrative metabolic disease business.

2024年12月19日 · Hoping to show the drug’s versatility, Vertex also sponsored a mid-stage trial focused on painful “lumbosacral radiculopathy,” or LSR, a common condition in which nerves in the lower back become compressed or irritated, leading to sharp bursts of …